CD19 and B-cell chronic lymphocytic leukemia: In one recent trial, 7 of 11 chronic lymphocytic leukemia (CLL) and lymphoma patients receiving NK cells, modified to express anti-CD19 CAR and IL-15, achieved complete remission without evidence of cytokine release syndrome.21